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Abstract Introduction: For routine staging of patients
with primary breast cancer, clinical practice guidelines
of many medical societies recommend chest X-ray, liver
ultrasound and bone scan. With respect to expanding
health care costs and patients’ psychological distress it
has been supposed, that there might be a group of breast
cancer patients, who do not need these imaging studies.
Methods: Four hundred and eighty-eight consecutive pa-
tients with primary breast cancer who had primary sur-
gery at our institution and complete work-up for distant
metastases including chest X-ray, liver ultrasound, and
bone scan were studied. Results: We found distant me-
tastases at the time of primary diagnosis in 19 patients
(3.9%). Bone metastases were found in 2.7%, liver me-
tastases in 1.0%, and pulmonary metastases in 0.4%.
However, in breast tumors smaller than 1 cm, no meta-
static lesions were found, whereas 18.2% of the patients
with pT4 tumors had metastases. In 2.4% of screening
imaging studies, metastases were ruled out by additional
imaging. Conclusion: Based on our data and a review of
the literature, we suggest that chest X-ray, liver ultra-
sound and bone scan can be omitted in the staging of
asymptomatic patients with pT1a or pT1b disease.
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Introduction
Screening of breast cancer patients for distant metastasis
at the time of presentation is required for staging and
subsequent management of these patients. In response 
to increasing demands for effectiveness of costs from
government and private third-party payers, health care
providers are asked to re-examine the current staging
strategies and to optimize utilization of resources. On the
other side as their patient’s advocate, they have to do
their best to exclude or detect metastatic lesions at initial
presentation in order to avoid over- and undertreatment.
In breast cancer patients, metastases are found most
frequently in bones, lung and liver, and therefore, the
staging methods recommended are bone scan, chest 
X-ray and liver ultrasound. In case of unclear findings,
further imaging studies such as computer tomography
(CT) or magnetic resonance imaging (MRI) will be per-
formed to confirm or rule out the presence of metastases.
The aim of this study was to determine the frequency
and distribution pattern of metastases at the time of pri-
mary surgery, and to identify a group of breast cancer
patients in whom imaging studies for staging can be
omitted.
Patients and methods
From January 1996 to June 2001, 497 consecutive patients with
primary breast cancer had surgery and subsequent therapy at the
Division of Gynecology of the University Hospital of Zurich,
Switzerland. Of these patients, 9 had incomplete staging due to si-
multaneous life limiting diseases or due to refusal, leaving 488 pa-
tients for further analysis. The mean age of these 488 patients was
60.9 years, ranging from 20 to 94 years. One hundred and forty
(28.7%) patients were premenopausal and 348 (71.3%) postmeno-
pausal. The patients were routinely staged with chest X-ray, liver
ultrasound and bone scan. The detection rate of metastases was
correlated with the size of the primary tumor as well as the pres-
ence of positive axillary lymph nodes. Staging was performed ac-
cording to the American Joint Committee on Cancer (AJCC) clas-
sification system [7].
Results
Metastases were found with routine imaging studies in
19 (3.9%) patients at the time of primary surgery. The
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most frequent location of metastasis was bone (2.7%),
followed by liver (1.0%) and lung (0.4%) (Table 1). 
Patients with pT1 tumor rarely had metastatic lesions.
Only 2 of 106 (1.3%) patients with pT1c tumors had dis-
tant metastases, all of which were bone metastases.
Moreover, both patients were node negative. In larger
primary tumors, metastatic lesions occurred in lymph
node positive breast cancer patients only. The highest
percentage of distant metastases had pT4d tumors with
30%. Patient and tumor characteristics of the 7 patients
with pT1–3 tumor and distant metastases are shown in
Table 2. 
Axillary lymph node dissection was routinely per-
formed in level I and II. In 268 (54.9%) patients the axil-
lary lymph nodes were negative at primary therapy. Only
2 (0.7%) of these had distant metastases (bone metastas-
es), detected by bone scan and confirmed with directed
X-ray studies. No lung or liver metastases were found in
node negative breast cancer patients at the time of prima-
ry surgery. Due to the suspicion of metastases in routine
staging, 19 (7.1%) node negative patients had 21 addi-
tional radiologic studies performed: directed X-rays of
bones in 10 cases, CT scan and/or MRI of the abdomen
in 8 cases and CT scans of the chest in 3 cases. Metasta-
tic lesions in all these 19 patients have been finally ruled
out.
Positive axillary lymph nodes were found in 216
(44.3%) patients. In 4 patients the nodal status was not
evaluable, mostly due to patients’ refusal to axillary sur-
gery or renunciation due to otherwise reduced life ex-
pectancy. None of these 4 patients had distant metastas-
es.
In the 216 patients with node positive breast cancer,
the diagnosis of distant metastases could be made by
bone scan, liver ultrasound or chest X-ray in 9 patients
(4.2%). Additional imaging studies were required in 22
of 216 patients (10.2%): 14 directed X-rays of bones, 
5 CT scans and/or MRI of the abdomen, 5 CT scans of
the chest and 1 CT scan of the bone. Only in 8 patients,
metastases were confirmed. Hence, 17 (7.9%) of the
node positive patients had distant metastases; one of
these patients had both bone and liver metastases. Four
patients with metastases had less then 4 positive axillary
lymph nodes (23.5%). Of 28 patients with axillary mi-
crometastasis (pN1a), one patient (3.6%) had detectable
bone metastases. The number of false positive imaging
studies routinely performed was high in both, node nega-
tive and node positive patients: In 4.3% of suspicious
bone scans, 1.0% of suspicious chest X-ray and 1.8% of
suspicious liver ultrasound, metastases were ruled out by
additional imaging studies.
Table 3 shows the correlation of the metastases and
stage according to AJCC classification. Of the 5 patients
with liver metastases, 3 had normal blood chemistry. The
other 2 have had either elevated transaminases or elevat-
ed alkaline phosphatase.
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Table 1 Frequency and distri-
bution pattern of metastases ac-
cording to the tumor size and
nodal status (n=484)
pT Nodal Number of Distant Bone Lung Liver
status patients metastases
1a + 2 0
– 18 0
1b + 3 0
– 35 0
1c + 45 0
– 106 2 (1.9%) 2 (1.9%) 0 0
2 + 93 3 (3.2%) 2 (2.2%) 0 1 (1.1%)
– 84 0
3 + 23 2 (8.7%) 1 (4.3%) 1 (4.3%) 0
– 10 0
4a–c + 40 9 (22.5%) 6 (15%) 1 (2.5%) 3 (7.5%)
– 11 0
4d + 10 3 (30%) 2 (20%) 0 1 (10%)
– 4 0
Table 2 Characteristics of
breast cancer patients with
pT1–3 tumors and metastases
Patient T-stage Tumor diameter Nodal Histological Estrogen receptor Location of
(mm) status grade status metastases
1 1c 15 Negative 2 ER+ Bone
2 1c 15 Negative 3 ER++++ Bone
3 2 21 Positive 1 ER++++ Bone
4 2 40 Positive 3 ER++++ Bone
5 2 22 Positive 2 ER++++ Liver
6 3 140 Positive 2 ER++++ Bone
7 3 55 Positive 2 ER++++ Lung
Discussion
Traditionally, chest X-ray, liver ultrasound and bone scan
are performed in all patients with breast cancer at the
time of first presentation to rule out lung, liver and bone
metastases. This work-up is recommended by many clin-
ical guidelines, e.g., the National Comprehensive Cancer
Network [2]. Only few studies have been focusing on the
necessity of these examinations in primary breast cancer,
despite expanding health care costs. It has been hypothe-
sized that staging examinations might be individualized
according to tumor size, nodal status and stage.
Bone is the most common location of distant metas-
tases in breast cancer. In a review of nine studies, the
rate of bone metastases at the time of primary surgery
was 3.1% [8]. In our study, we found an overall rate of
2.7%. However, no patient with pT1a or pT1b disease
was found to have distant metastases. Bone metastases
were found in 1.3% of our patients with pT1 pN0 dis-
ease, which is in good agreement with the rates reported
by Ciatto et al. [4] and Cox et al. [5]. In patients with
presumable stage II disease, 1.3% of our patients had de-
tectable distant metastases, which is similar to other re-
ports [4, 5]. While 9.7% of our patients with presumable
stage III disease had a skeletal involvement, Ciatto et al.
[4] detected bone metastases in 1.2% and Cox et al. [5]
in 16.2%.
Pulmonary metastases were present in only 2 of 488
patients (1.0%). Both patients had presumable stage III
disease. This is similar to the rate of 0.3% reported by
Ciatto et al. [4]. Chen et al. [3] reported an detection rate
of 0.099% for asymptomatic lung metastases in 1003 pa-
tients. Although many anesthesiologists traditionally re-
quire chest X-ray before general anesthesia, there is no
strong medical indication for routine preoperative chest
X-ray in asymptomatic, otherwise healthy breast cancer
patients [13]. Furthermore, chest X-ray has never been
shown to improve outcome in the care of patients with
clinical stage I and II breast cancer [3]. Our data support
the view that chest X-ray may be eliminated in the 
routine staging for asymptomatic patients with stage I or
II breast cancer.
Liver metastases at the time of primary therapy are
described in 0.3 to 0.5% [1, 4]. In our study, we found
liver metastases in 5 patients (1.0%). Accordant to the
results of Ciatto et al. [4], we never found liver metastas-
es in patients with stage I breast cancer. In presumable
stage II disease, we detected liver involvement in 1 pa-
tient (0.4%). In agreement with other studies [5, 6], 4.3%
of our patients with presumable stage III disease had 
liver metastases at the time of primary surgery. Myers 
et al. [8] and Ravaioli et al. [10, 11] conclude that liver
ultrasound can be omitted in the work-up of stage I and
II breast cancer unless symptoms or blood chemistry
suggest liver metastases. With this strategy, we would
have missed one patient with stage II disease with
asymptomatic liver metastases and normal blood chemis-
try.
Based on our results and a review of the literature, it
is reasonable and safe to reduce costs by omitting routine
staging imaging studies of asymptomatic patients with
pT1a and pT1b tumors. In patients with pT1c tumors
routine staging yielded distant metastases in 1.3% of 
patients. Therefore, we believe that routine work-up 
for distant metastases should not be omitted in pT1c 
patients. Calculations on cost savings were made by 
Norum and Andreassen [9]. They suggested to screen
patients in stage I and stage II breast cancer with less
than five affected axillary lymph nodes by chest X-ray
and blood tests only. According to their calculation, this
strategy resulted in significant cost savings without in-
fluencing survival. By omitting imaging studies for
asymptomatic patients with pT1a and pT1b disease, we
recommend a more conservative strategy than others,
since these publications accept a rate of missed metastat-
ic disease up to 3% [8, 11, 12]. Using our approach, im-
aging studies for staging would have been omitted in 58
patients (11.9%) without missing distant metastases and
two of 35 false-positive imaging studies would have
been avoided (5.7%).
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Table 3 Frequency of distant
metastases according to the
stage (AJCC classification)
Study Stage Distant metastases
Bone Lung Liver
Present study I 1.3% (2/159) 0 (0/159) 0 (0/159)
II 0.8% (2/233) 0 (0/233) 0.4% (1/233)
III 9.7% (9/93) 2.2% (2/93) 4.3% (4/93)
[4] I 0.2% (1/550) 0.1% (1/873) 0 (0/132)
II 1.1% (14/1317) 0.2% (3/1943) 0.2% (1/462)
III 1.2% (6/508) 1.0% (7/682) 0.5% (1/194)
[5] I 0.8% (1/122) 0 (0/127)
II 1.1% (2/180) 0 (0/182)
III 16.2% (6/37) 5.4% (2/37)
[6] I 0 (0/64) 0 (0/54)
II 0.8% (2/240) 1.8% (3/167)
III 7.3% (6/82) 4.0% (2/50)
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